Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
46,691,176
-
Number of holders
-
54
-
Total 13F shares, excl. options
-
16,612,608
-
Shares change
-
+1,228,094
-
Total reported value, excl. options
-
$400,026,000
-
Value change
-
+$731,531
-
Number of buys
-
40
-
Number of sells
-
-29
-
Price
-
$24.08
Significant Holders of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) as of Q2 2021
72 filings reported holding FDMT - 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2021.
4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) has 54 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16,612,608 shares
of 46,691,176 outstanding shares and own 35.58% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (3,937,914 shares), BVF INC/IL (2,005,862 shares), JANUS HENDERSON GROUP PLC (1,539,726 shares), Casdin Capital, LLC (1,115,555 shares), FMR LLC (1,037,726 shares), ArrowMark Colorado Holdings LLC (1,029,897 shares), Aquilo Capital Management, LLC (945,382 shares), Octagon Capital Advisors LP (831,267 shares), BlackRock Inc. (731,410 shares), and ALKEON CAPITAL MANAGEMENT LLC (502,926 shares).
This table shows the top 54 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.